The purpose of this study is to evaluate the contribution of the imaging to the expression of intégrines αvβ3 for the characterization of the residual masses of non-seminoma tumors at the end of chemotherapy. The investigators hope that the results of this first stage of the clinical trial come to consolidate the preclinical results obtained by the investigators team to characterizing the interest and the strong contribution of the use of a tracer resting on the expression of αvβ3 integrine for the diagnosis of simple necrosed mass at the end of the treatment of a non-seminoma tumor, so allowing to defer a surgery to about 40 % of the patients.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
16
Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
CHU
Caen, France
Centre François Baclesse
Caen, France
Centre Henri Becquerel
Rouen, France
CHU Rouen
Rouen, France
Institut Claudius Regaud
Toulouse, France
Proportion of teratoma
Efficacity to differentiate mature teratoma and necroses within the residual masses of germinal non-seminoma tumors.
Time frame: up to 6 weeks
Metabolic profile
Number of patients having at least a tumor detected by TEP K5-RGD requiring a surgery, divided by the number of patients having actually at least a tumor (by anatomopathologie) requiring a chirurgie
Time frame: up to 10 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.